97 related articles for article (PubMed ID: 1977603)
1. Optically active benzamides as predictive tools for mapping the dopamine D2 receptor.
Rognan D; Sokoloff P; Mann A; Martres MP; Schwartz JC; Costentin J; Wermuth CG
Eur J Pharmacol; 1990 Jul; 189(1):59-70. PubMed ID: 1977603
[TBL] [Abstract][Full Text] [Related]
2. Potential antipsychotic agents. 9. Synthesis and stereoselective dopamine D-2 receptor blockade of a potent class of substituted (R)-N-[(1-benzyl-2-pyrrolidinyl)methyl]benzamides. Relations to other side chain congeners.
Högberg T; Ström P; de Paulis T; Stensland B; Csöregh I; Lundin K; Hall H; Ogren SO
J Med Chem; 1991 Mar; 34(3):948-55. PubMed ID: 1672158
[TBL] [Abstract][Full Text] [Related]
3. Conformational analysis and molecular modeling of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as D1 dopamine receptor ligands.
Charifson PS; Bowen JP; Wyrick SD; Hoffman AJ; Cory M; McPhail AT; Mailman RB
J Med Chem; 1989 Sep; 32(9):2050-8. PubMed ID: 2527994
[TBL] [Abstract][Full Text] [Related]
4. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.
Ohmori J; Maeno K; Hidaka K; Nakato K; Matsumoto M; Tada S; Hattori H; Sakamoto S; Tsukamoto S; Usuda S; Mase T
J Med Chem; 1996 Jul; 39(14):2764-72. PubMed ID: 8709107
[TBL] [Abstract][Full Text] [Related]
5. Antidopaminergic effects of the stereoisomers of N-[(1-alkyl-2- pyrrolidinyl)methyl]-5-sulfamoylbenzamides and -2,3-dihydrobenzofuran-7-carboxamides.
Murakami S; Marubayashi N; Fukuda T; Takehara S; Tahara T
J Med Chem; 1991 Jan; 34(1):261-7. PubMed ID: 1825115
[TBL] [Abstract][Full Text] [Related]
6. Investigation on central dopaminergic receptors (D-2) using the antagonistic properties of new benzamides.
Rumigny JF; Strolin Benedetti M; Dostert P
J Pharm Pharmacol; 1984 Jun; 36(6):373-7. PubMed ID: 6146667
[TBL] [Abstract][Full Text] [Related]
7. Substituted benzamides with conformationally restricted side chains. 2. Indolizidine derivatives as central dopamine receptor antagonists.
King FD; Hadley MS; McClelland CM
J Med Chem; 1988 Sep; 31(9):1708-12. PubMed ID: 2900897
[TBL] [Abstract][Full Text] [Related]
8. Conformational analysis of dopamine D-2 receptor antagonists of the benzamide series in relation to a recently proposed D-2 receptor-interaction model.
Pettersson I; Liljefors T
J Med Chem; 1992 Jun; 35(13):2355-63. PubMed ID: 1535660
[TBL] [Abstract][Full Text] [Related]
9. The incorporation of butyrophenones and related compounds into a pharmacophore for dopamine D2 antagonists.
Froimowitz M; Cody V
Drug Des Discov; 1997 Aug; 15(2):63-81. PubMed ID: 9342550
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for Na(+)-sensitivity in dopamine D2 and D3 receptors.
Michino M; Free RB; Doyle TB; Sibley DR; Shi L
Chem Commun (Camb); 2015 May; 51(41):8618-21. PubMed ID: 25896577
[TBL] [Abstract][Full Text] [Related]
11. The development of dopamine D2-receptor selective antagonists.
Högberg T
Drug Des Discov; 1993; 9(3-4):333-50. PubMed ID: 8400011
[TBL] [Abstract][Full Text] [Related]
12. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and binding properties of the fluorinated substituted benzamide [3H]NCQ 115, a new selective dopamine D2 receptor ligand.
Hall H; Högberg T; Halldin C; Bengtsson S; Wedel I
Eur J Pharmacol; 1991 Aug; 201(1):1-10. PubMed ID: 1686586
[TBL] [Abstract][Full Text] [Related]
14. Remoxipride shows low propensity to block functional striatal dopamine D2 receptors in vitro.
Westlind-Danielsson A; Gustafsson K; Andersson I
Eur J Pharmacol; 1994 Dec; 288(1):89-95. PubMed ID: 7705472
[TBL] [Abstract][Full Text] [Related]
15. Discriminative stimulus properties of the atypical antipsychotic amisulpride: comparison to its isomers and to other benzamide derivatives, antipsychotic, antidepressant, and antianxiety drugs in C57BL/6 mice.
Donahue TJ; Hillhouse TM; Webster KA; Young R; De Oliveira EO; Porter JH
Psychopharmacology (Berl); 2017 Dec; 234(23-24):3507-3520. PubMed ID: 28921163
[TBL] [Abstract][Full Text] [Related]
16. Dopamine D2 receptor model explains binding affinity of neuroleptics: piquindone and its structure activity relationships.
Teeter MM; Durand CJ
Drug Des Discov; 1996 Apr; 13(3-4):49-62. PubMed ID: 8874043
[No Abstract] [Full Text] [Related]
17. Effect of substituted benzamides on prolactin secretion in the rat.
Kakigi T; Maeda K; Tanimoto K; Kaneda H; Shintani T
Biol Psychiatry; 1992 Apr; 31(8):827-31. PubMed ID: 1353691
[No Abstract] [Full Text] [Related]
18. A multiway 3D QSAR analysis of a series of (S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-methoxybenzamides.
Nilsson J; Homan EJ; Smilde AK; Grol CJ; Wikström H
J Comput Aided Mol Des; 1998 Jan; 12(1):81-93. PubMed ID: 9570091
[TBL] [Abstract][Full Text] [Related]
19. Studies of the active conformation of a novel series of benzamide dopamine D2 agonists.
Wustrow DJ; Wise LD; Cody DM; MacKenzie RG; Georgic LM; Pugsley TA; Heffner TG
J Med Chem; 1994 Nov; 37(24):4251-7. PubMed ID: 7990124
[TBL] [Abstract][Full Text] [Related]
20. [The inhibition of dopamine D1 and D2 receptors in human putamen by antipsychotic drugs].
Kobayashi T; Shimizu H; Toru M
Yakubutsu Seishin Kodo; 1990 Jun; 10(2):331-4. PubMed ID: 1979198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
